Studies Exploring Nipent® in Combination Cancer Therapies in the Treatment of Graft-Versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting

Studies Exploring Nipent(R) in Combination Cancer Therapies in the Treatment of Graft - Versus Host Disease (GVHD) Presented at American Society of Hematology Annual Meeting DUBLIN, Calif., Dec 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- SuperGen, Inc. (Nasdaq: SUPG) announced that abstracts from eight studies of its anticancer drug Nipent ® (pentostatin for injection) were presented this week during the proceedings of the American Society Hematology Annual Meeting in San Diego, California. The eight abstracts, which were presented during the General Poster Sessions and in various oral symposia, discussed the use of Nipent in combination with other chemotherapeutic agents, to treat chemotherapy -naive B-cell Chronic Lymphocytic Leukemia and Hairy Cell Leukemia patients. A novel regimen of pentostatin, cyclophosphamide and rituximab (PCR) demonstrated clinical activity in B-cell Chronic Lymphocytic Leukemia with modest toxicity. Pentostatin also demonstrated utility as an immunosuppressive treatment prior to donor lymphocyte infusion (DLI) for patients at risk for graft rejection after Hematopoietic Cell Transplantation (HCT). The drug showed particular activity in the treatment of children and adolescents with chronic graft versus host disease (cGVHD), and in high -risk patients undergoing reduced intensity transplantation regimens. The eight abstracts referring to pentostatin are available online at http://www.hematology.org. 1. Abstract #1246 appears in Blood, Volume 103, issue 12, November 16, 2004 Keywords: Bone marrow transplant/Pentostatin/Photopheresis 2. Abstract #2249 appears in Blood, Volume 103, issue 12, November 16, 2004 Keywords: Chronic graft -versus- host/Pentostatin/Pediatric 3. Abstract #186 appears in Blood, Volume 103, issue 12, November 16, 2004 Keywords: Rejection/DLI/Non -myeloablative 4. Abstract #339 appears in Blood, Volume 103, issue 12, November 16, 2004 Keywords: FISH/Therapy/Risk factor 5. Abstract #3472 appears in Blood, Volume 103, issue 12, November 16, 2004 Keywords: Hairy cell leukemia/Pentostatin/Cladribine 6. Abstract #3473 appears in Blood, Volume 103, issue 12, November 16, 2004 Keywords: Hairy cell leukemia/Long -term follow-up/Cladribine 7. Abstract #3484 appears in Blood, Volume 103, issue 12, November 16, 2004 Keywords: Chronic lymphocytic leukemia/Pentostatin/Salvage chemotherapy 8. Abstract #727 appears in Blood, Volume 103, issue 12, November 16, 2004 Keywords: Unrelated donor stem cell transplant/Graft -versus-host disease (GVHD)/Pentostatin About Nipent Nipent® is currently approved as a single -agent treatment for patients with hairy cell leukemia and is not approved as either a single agent or as part of a combination regimen for treatment for any other indication. About SuperGen Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. The company's website can be reached at http://www.supergen.com. Contacts: SuperGen, Inc. Euro RSCG Life NRP Timothy L. Enns Sharon Weinstein (925) 560-0100 x111 (212) 845-4271 [email protected] [email protected] SOURCE SuperGen, Inc. http://www.supergen.com

The release as fetched from its publisher. astx.com ↗